VANDA PHARMACEUTICALS INC. Investing Cash Flow
VANDA PHARMACEUTICALS INC. (VNDA) reported Investing Cash Flow of $54.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-06
- VANDA PHARMACEUTICALS INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $33.81M.
- VANDA PHARMACEUTICALS INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $20.23M, a 53.91% decline year-over-year.
- VANDA PHARMACEUTICALS INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $44.87M, a 1023.62% increase year-over-year.
- VANDA PHARMACEUTICALS INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $21.36M, a 77.18% increase year-over-year.
- VANDA PHARMACEUTICALS INC. net cash provided by (used in) investing activities for fiscal 2025 was $94.86M.
- VANDA PHARMACEUTICALS INC. net cash provided by (used in) investing activities for fiscal 2024 was -$17.43M.
- VANDA PHARMACEUTICALS INC. net cash provided by (used in) investing activities for fiscal 2023 was -$12.06M, a 124.15% decline from fiscal 2022.
- VANDA PHARMACEUTICALS INC. net cash provided by (used in) investing activities for fiscal 2022 was $49.92M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $33.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $54.04M 10-Q · filed 2026-08-06 | $98.91M derived: sum of 3 quarters · filed 2026-08-06 | $120.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $20.23M 10-Q · filed 2026-05-07 | $65.10M derived: sum of 2 quarters · filed 2026-05-07 | $86.46M derived: sum of 3 quarters · filed 2026-05-07 | $71.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $44.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $66.23M derived: sum of 2 quarters · filed 2026-02-12 | $50.96M derived: sum of 3 quarters · filed 2026-08-06 | $94.86M 10-K · filed 2026-02-12 |
| 2025-09-30 | $21.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $6.09M derived: sum of 2 quarters · filed 2026-08-06 | $49.99M 10-Q · filed 2025-10-30 | $53.99M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$15.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $28.63M 10-Q · filed 2026-08-06 | $32.63M derived: sum of 3 quarters · filed 2026-08-06 | $44.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $43.90M 10-Q · filed 2026-05-07 | $47.90M derived: sum of 2 quarters · filed 2026-05-07 | $59.95M derived: sum of 3 quarters · filed 2026-05-07 | $44.69M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $3.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $16.05M derived: sum of 2 quarters · filed 2026-02-12 | $788.00K derived: sum of 3 quarters · filed 2026-02-12 | -$17.43M 10-K · filed 2026-02-12 |
| 2024-09-30 | $12.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$3.21M derived: sum of 2 quarters · filed 2025-10-30 | -$21.42M 10-Q · filed 2025-10-30 | -$65.21M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | -$15.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$33.48M 10-Q · filed 2025-07-31 | -$77.26M derived: sum of 3 quarters · filed 2026-02-12 | -$41.94M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | -$18.22M 10-Q · filed 2025-05-08 | -$62.00M derived: sum of 2 quarters · filed 2026-02-12 | -$26.67M derived: sum of 3 quarters · filed 2026-02-12 | -$217.57M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | -$43.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$8.46M derived: sum of 2 quarters · filed 2026-02-12 | -$199.35M derived: sum of 3 quarters · filed 2026-02-12 | -$12.06M 10-K · filed 2026-02-12 |
| 2023-09-30 | $35.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$155.57M derived: sum of 2 quarters · filed 2024-11-07 | $31.73M 10-Q · filed 2024-11-07 | $107.16M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-06-30 | -$190.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$3.60M 10-Q · filed 2024-08-01 | $71.83M derived: sum of 3 quarters · filed 2025-02-14 | $50.05M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-03-31 | $187.29M 10-Q · filed 2024-05-09 | $262.72M derived: sum of 2 quarters · filed 2025-02-14 | $240.94M derived: sum of 3 quarters · filed 2025-02-14 | $226.35M derived: sum of 4 quarters · filed 2025-02-14 |
| 2022-12-31 | $75.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $53.65M derived: sum of 2 quarters · filed 2025-02-14 | $39.06M derived: sum of 3 quarters · filed 2025-02-14 | $49.92M 10-K · filed 2025-02-14 |
| 2022-09-30 | -$21.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$36.37M derived: sum of 2 quarters · filed 2023-11-09 | -$25.50M 10-Q · filed 2023-11-09 | -$51.50M derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-06-30 | -$14.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-28 | -$3.73M 10-Q · filed 2023-07-28 | -$29.72M derived: sum of 3 quarters · filed 2024-02-08 | -$46.31M derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-03-31 | $10.87M 10-Q · filed 2023-05-03 | -$15.13M derived: sum of 2 quarters · filed 2024-02-08 | -$31.72M derived: sum of 3 quarters · filed 2024-02-08 | -$65.90M derived: sum of 4 quarters · filed 2024-02-08 |
| 2021-12-31 | -$26.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-08 | -$42.59M derived: sum of 2 quarters · filed 2024-02-08 | -$76.77M derived: sum of 3 quarters · filed 2024-02-08 | -$76.70M 10-K · filed 2024-02-08 |
| 2021-09-30 | -$16.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$50.77M derived: sum of 2 quarters · filed 2022-11-03 | -$50.70M 10-Q · filed 2022-11-03 | -$67.38M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-06-30 | -$34.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$34.11M 10-Q · filed 2022-08-04 | -$50.80M derived: sum of 3 quarters · filed 2023-02-09 | -$98.64M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-03-31 | $71.00K 10-Q · filed 2022-05-06 | -$16.61M derived: sum of 2 quarters · filed 2023-02-09 | -$64.46M derived: sum of 3 quarters · filed 2023-02-09 | -$61.73M derived: sum of 4 quarters · filed 2023-02-09 |
| 2020-12-31 | -$16.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | -$64.53M derived: sum of 2 quarters · filed 2023-02-09 | -$61.80M derived: sum of 3 quarters · filed 2023-02-09 | -$41.50M 10-K · filed 2023-02-09 |
| 2020-09-30 | -$47.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$45.11M derived: sum of 2 quarters · filed 2021-11-04 | -$24.81M 10-Q · filed 2021-11-04 | -$31.04M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $2.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $23.03M 10-Q · filed 2021-07-29 | $16.80M derived: sum of 3 quarters · filed 2022-02-24 | $2.93M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $20.30M 10-Q · filed 2021-05-06 | $14.07M derived: sum of 2 quarters · filed 2022-02-24 | $196.00K derived: sum of 3 quarters · filed 2022-02-24 | -$11.56M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | -$6.23M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$20.10M derived: sum of 2 quarters · filed 2022-02-24 | -$31.86M derived: sum of 3 quarters · filed 2022-02-24 | -$68.31M 10-K · filed 2022-02-24 |
| 2019-09-30 | -$13.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | -$25.63M derived: sum of 2 quarters · filed 2020-10-29 | -$62.08M 10-Q · filed 2020-10-29 | -$77.88M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | -$11.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$48.20M 10-Q · filed 2020-08-06 | -$64.01M derived: sum of 3 quarters · filed 2021-02-11 | |
| 2019-03-31 | -$36.45M 10-Q · filed 2020-05-07 | -$52.26M derived: sum of 2 quarters · filed 2021-02-11 | ||
| 2018-12-31 | -$15.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | -$109.66M 10-K · filed 2021-02-11 | ||
| 2018-09-30 | -$93.86M 10-Q · filed 2019-11-07 | |||
| 2017-12-31 | -$10.23M 10-K · filed 2020-02-26 | |||
| 2014-03-31 | $389.00K 10-Q · filed 2014-05-08 | -$65.31M derived: sum of 2 quarters · filed 2014-05-08 | -$65.31M derived: sum of 3 quarters · filed 2014-05-08 | -$64.36M derived: sum of 4 quarters · filed 2014-05-08 |
| 2013-12-31 | -$65.70M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | -$65.70M derived: sum of 2 quarters · filed 2014-02-25 | -$64.75M derived: sum of 3 quarters · filed 2014-02-25 | -$34.27M 10-K · filed 2014-02-25 |
| 2013-09-30 | -$7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $944.00K derived: sum of 2 quarters · filed 2013-11-08 | $31.42M 10-Q · filed 2013-11-08 | $29.52M derived: sum of 4 quarters · filed 2014-05-08 |
| 2013-06-30 | $951.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-31 | $31.43M 10-Q · filed 2013-07-31 | $29.52M derived: sum of 3 quarters · filed 2014-05-08 | $49.81M derived: sum of 4 quarters · filed 2014-05-08 |
| 2013-03-31 | $30.48M 10-Q · filed 2014-05-08 | $28.57M derived: sum of 2 quarters · filed 2014-05-08 | $48.86M derived: sum of 3 quarters · filed 2014-05-08 | $47.37M derived: sum of 4 quarters · filed 2014-05-08 |
| 2012-12-31 | -$1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $18.39M derived: sum of 2 quarters · filed 2014-02-25 | $16.89M derived: sum of 3 quarters · filed 2014-02-25 | $45.75M 10-K · filed 2014-02-25 |
| 2012-09-30 | $20.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $18.80M derived: sum of 2 quarters · filed 2013-11-08 | $47.66M 10-Q · filed 2013-11-08 | $87.59M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-06-30 | -$1.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-31 | $27.37M 10-Q · filed 2013-07-31 | $67.30M derived: sum of 3 quarters · filed 2014-02-25 | $84.41M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-03-31 | $28.86M 10-Q · filed 2013-05-10 | $68.80M derived: sum of 2 quarters · filed 2014-02-25 | $85.90M derived: sum of 3 quarters · filed 2014-02-25 | $89.39M derived: sum of 4 quarters · filed 2014-02-25 |
| 2011-12-31 | $39.93M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $57.04M derived: sum of 2 quarters · filed 2014-02-25 | $60.52M derived: sum of 3 quarters · filed 2014-02-25 | $73.75M 10-K · filed 2014-02-25 |
| 2011-09-30 | $17.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $20.59M derived: sum of 2 quarters · filed 2012-11-08 | $33.81M 10-Q · filed 2012-11-08 | -$22.34M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-06-30 | $3.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | $16.71M 10-Q · filed 2012-08-03 | -$39.45M derived: sum of 3 quarters · filed 2013-02-26 | -$77.60M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-03-31 | $13.22M 10-Q · filed 2012-05-09 | -$42.94M derived: sum of 2 quarters · filed 2013-02-26 | -$81.09M derived: sum of 3 quarters · filed 2013-02-26 | |
| 2010-12-31 | -$56.16M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$94.31M derived: sum of 2 quarters · filed 2013-02-26 | -$155.62M 10-K · filed 2013-02-26 | |
| 2010-09-30 | -$38.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | -$99.46M 10-Q · filed 2011-11-07 | ||
| 2010-06-30 | -$61.31M 10-Q · filed 2011-08-05 | |||
| 2009-12-31 | -$4.74M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |